|
1
|
Hu Z, Li M, Chen Z, Zhan C, Lin Z and Wang
Q: Advances in clinical trials of targeted therapy and
immunotherapy of lung cancer in 2018. Transl Lung Cancer Res.
8:1091–1106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dela Cruz CS, Tanoue LT and Matthay RA:
Lung cancer: Epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carter BW, Lichtenberger JP III,
Benveniste MK, de Groot PM, Wu CC, Erasmus JJ and Truong MT:
Revisions to the TNM staging of lung cancer: Rationale,
significance, and clinical application. Radiographics. 38:374–391.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park HK, Han BR and Park WH: Combination
of arsenic trioxide and valproic acid efficiently inhibits growth
of lung cancer cells via G2/M-phase arrest and apoptotic cell
death. Int J Mol Sci. 21:26492020. View Article : Google Scholar
|
|
5
|
You BR and Park WH: Suberoyl bishydroxamic
acid inhibits the growth of A549 lung cancer cells via
caspase-dependent apoptosis. Mol Cell Biochem. 344:203–210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chung C: Restoring the switch for cancer
cell death: Targeting the apoptosis signaling pathway. Am J Health
Syst Pharm. 75:945–952. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Würstle ML, Laussmann MA and Rehm M: The
central role of initiator caspase-9 in apoptosis signal
transduction and the regulation of its activation and activity on
the apoptosome. Exp Cell Res. 318:1213–1220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huska JD, Lamb HM and Hardwick JM:
Overview of BCL-2 family proteins and therapeutic potentials.
Methods Mol Biol. 1877:1–21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Yue P, Zhou Z, Khuri FR and Sun SY:
Death receptor regulation and celecoxib-induced apoptosis in human
lung cancer cells. J Natl Cancer Inst. 96:1769–1780. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Onodera T, Momose I and Kawada M:
Potential anticancer activity of auranofin. Chem Pharm Bull
(Tokyo). 67:186–191. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Isakov E, Weisman-Shomer P and Benhar M:
Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in
macrophages by the thioredoxin reductase inhibitor auranofin.
Biochim Biophys Acta. 1840:3153–3161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
You BR and Park WH: Auranofin induces
mesothelioma cell death through oxidative stress and GSH depletion.
Oncol Rep. 35:546–551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park WH and You BR: Antimycin A induces
death of the human pulmonary fibroblast cells via ROS increase and
GSH depletion. Int J Oncol. 48:813–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fernandes AP, Capitanio A, Selenius M,
Brodin O, Rundlöf AK and Björnstedt M: Expression profiles of
thioredoxin family proteins in human lung cancer tissue:
Correlation with proliferation and differentiation. Histopathology.
55:313–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hawkes HJ, Karlenius TC and Tonissen KF:
Regulation of the human thioredoxin gene promoter and its key
substrates: A study of functional and putative regulatory elements.
Biochim Biophys Acta. 1840:303–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu
S, Li L, Tong P, Wang J, Meng QH, et al: Inhibition of
thioredoxin/thioredoxin reductase induces synthetic lethality in
lung cancers with compromised glutathione homeostasis. Cancer Res.
79:125–132. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fu JN, Li J, Tan Q, Yin HW, Xiong K, Wang
TY, Ren XY and Zeng HH: Thioredoxin reductase inhibitor ethaselen
increases the drug sensitivity of the colon cancer cell line LoVo
towards cisplatin via regulation of G1 phase and reversal of G2/M
phase arrest. Invest New Drugs. 29:627–636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Poerschke RL and Moos PJ: Thioredoxin
reductase 1 knockdown enhances selenazolidine cytotoxicity in human
lung cancer cells via mitochondrial dysfunction. Biochem Pharmacol.
81:211–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
You BR and Park WH: Down-regulation of
thioredoxin1 is involved in death of Calu-6 lung cancer cells
treated with suberoyl bishydroxamic acid. J Cell Biochem.
117:1250–1261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
You BR, Shin HR, Han BR, Kim SH and Park
WH: Auranofin induces apoptosis and necrosis in HeLa cells via
oxidative stress and glutathione depletion. Mol Med Rep.
11:1428–1434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park WH: Hydrogen peroxide inhibits the
growth of lung cancer cells via the induction of cell death and
G1-phase arrest. Oncol Rep. 40:1787–1794. 2018.PubMed/NCBI
|
|
23
|
Park WH, Seol JG, Kim ES, Hyun JM, Jung
CW, Lee CC, Kim BK and Lee YY: Arsenic trioxide-mediated growth
inhibition in MC/CAR myeloma cells via cell cycle arrest in
association with induction of cyclin-dependent kinase inhibitor,
p21, and apoptosis. Cancer Res. 60:3065–3071. 2000.PubMed/NCBI
|
|
24
|
Marzano C, Gandin V, Folda A, Scutari G,
Bindoli A and Rigobello MP: Inhibition of thioredoxin reductase by
auranofin induces apoptosis in cisplatin-resistant human ovarian
cancer cells. Free Radic Biol Med. 42:872–881. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shin DW, Kwon YJ, Ye DJ, Baek HS, Lee JE
and Chun YJ: Auranofin suppresses plasminogen activator inhibitor-2
expression through annexin a5 induction in human prostate cancer
cells. Biomol Ther (Seoul). 25:177–185. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fidyt K, Pastorczak A, Goral A, Szczygiel
K, Fendler W, Muchowicz A, Bartlomiejczyk MA, Madzio J, Cyran J,
Graczyk-Jarzynka A, et al: Targeting the thioredoxin system as a
novel strategy against B-cell acute lymphoblastic leukemia. Mol
Oncol. 13:1180–1195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mandal PK, Schneider M, Kölle P,
Kuhlencordt P, Förster H, Beck H, Bornkamm GW and Conrad M: Loss of
thioredoxin reductase 1 renders tumors highly susceptible to
pharmacologic glutathione deprivation. Cancer Res. 70:9505–9514.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wen C, Wang H, Wu X, He L, Zhou Q, Wang F,
Chen S, Huang L, Chen J, Wang H, et al: ROS-mediated inactivation
of the PI3K/AKT pathway is involved in the antigastric cancer
effects of thioredoxin reductase-1 inhibitor chaetocin. Cell Death
Dis. 10:8092019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Radenkovic F, Holland O, Vanderlelie JJ
and Perkins AV: Selective inhibition of endogenous antioxidants
with Auranofin causes mitochondrial oxidative stress which can be
countered by selenium supplementation. Biochem Pharmacol.
146:42–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mejia EM and Hatch GM: Mitochondrial
phospholipids: Role in mitochondrial function. J Bioenerg Biomembr.
48:99–112. 2016. View Article : Google Scholar : PubMed/NCBI
|
